Baidu
map

感染

订阅

MedSci主页 / 所有栏目 / 感染

SCI REP：预测HR+/HER2-早期乳腺癌远处转移的新方法

2017-03-29 MedSci MedSci原创

乳腺癌远处转移危险因素
关注

激素受体阳性（HR+）乳腺癌包括HR+/HER2+以及HR+/HER2-两种，其中HR+/HER2-乳腺癌是最常见的亚型。HR+/HER2-乳腺癌患者经过激素治疗后HR+/HER2+或HR-的患者相比5年远期复发率更高。对于这类乳腺癌患者，准确评估远期复发风险对治疗有重要意义。

激素受体阳性（HR+）乳腺癌包括HR+/HER2+以及HR+/HER2-两种，其中HR+/HER2-乳腺癌是最常见的亚型。HR+/HER2-乳腺癌患者经过激素治疗后HR+/HER2+或HR-的患者相比5年远期复发率更高。对于这类乳腺癌患者，准确评估远期复发风险对治疗有重要意义。

SCI REP近期发表了一篇文章，建立新的预测HR+/HER2-仅接受激素治疗的乳腺癌患者远处转移风险的方法。从福尔马林固定、石蜡包埋的肿瘤组织中提取RNA，使用PCR的方法检测基因表达。六种主要的预后基因与两种临床变量（淋巴结状态以及肿瘤大小）结合计算风险评分（BCT评分）。在仅接受激素治疗的研究组，BCT评分判定的高风险组10年远处转移的风险显着高于低风险组（P<0.001）。根据临床变量调整后的多因素分析表明BCT评分是远处转移的独立预测因素。BCT评分的预测效力要优于传统的基于临床病理参数模型的预测效力。

BCT评分对HR+/HER2-的早期乳腺癌患者的远处转移预测效力优于传统临床病理特征的模型。BCT评分有助于判断N0-N1，HR+/HER2-乳腺癌患者是否需要额外的辅助治疗。

原始出处：

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1982506, encodeId=e17719825067e, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Aug 18 02:24:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903198, encodeId=3cde19031986d, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Feb 10 12:24:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423486, encodeId=0854142348658, content=<a href='/topic/show?id=badd9441868' target=_blank style='color:#2F92EE;'>#远处转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94418, encryptionId=badd9441868, topicName=远处转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c42b3793913, createdName=hanhaisha2009, createdTime=Fri Mar 31 04:24:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=183530, encodeId=22c4183530ff, content=说的好，科学前言, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170114/IMG587A0E092CFCA5835.jpg, createdBy=eac02002225, createdName=爱的天使, createdTime=Wed Mar 29 14:19:18 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
    2017-08-18 luwei00

    #HER2-#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1982506, encodeId=e17719825067e, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Aug 18 02:24:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903198, encodeId=3cde19031986d, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Feb 10 12:24:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423486, encodeId=0854142348658, content=<a href='/topic/show?id=badd9441868' target=_blank style='color:#2F92EE;'>#远处转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94418, encryptionId=badd9441868, topicName=远处转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c42b3793913, createdName=hanhaisha2009, createdTime=Fri Mar 31 04:24:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=183530, encodeId=22c4183530ff, content=说的好，科学前言, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170114/IMG587A0E092CFCA5835.jpg, createdBy=eac02002225, createdName=爱的天使, createdTime=Wed Mar 29 14:19:18 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
    2018-02-10 kord1982

    #新方法#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1982506, encodeId=e17719825067e, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Aug 18 02:24:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903198, encodeId=3cde19031986d, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Feb 10 12:24:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423486, encodeId=0854142348658, content=<a href='/topic/show?id=badd9441868' target=_blank style='color:#2F92EE;'>#远处转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94418, encryptionId=badd9441868, topicName=远处转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c42b3793913, createdName=hanhaisha2009, createdTime=Fri Mar 31 04:24:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=183530, encodeId=22c4183530ff, content=说的好，科学前言, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170114/IMG587A0E092CFCA5835.jpg, createdBy=eac02002225, createdName=爱的天使, createdTime=Wed Mar 29 14:19:18 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
    2017-03-31 hanhaisha2009

    #远处转移#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1982506, encodeId=e17719825067e, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Aug 18 02:24:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903198, encodeId=3cde19031986d, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Feb 10 12:24:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423486, encodeId=0854142348658, content=<a href='/topic/show?id=badd9441868' target=_blank style='color:#2F92EE;'>#远处转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94418, encryptionId=badd9441868, topicName=远处转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c42b3793913, createdName=hanhaisha2009, createdTime=Fri Mar 31 04:24:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=183530, encodeId=22c4183530ff, content=说的好，科学前言, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170114/IMG587A0E092CFCA5835.jpg, createdBy=eac02002225, createdName=爱的天使, createdTime=Wed Mar 29 14:19:18 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
    2017-03-29 爱的天使

    说的好，科学前言

    0

相关资讯

Sci Rep:用抗体接株高分子实现对乳腺癌细胞的选择性给药

一篇名为Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer的文章发表在《科学报告》上，文章利用特定抗体接株的树形高分子实现了对HER-2阳性乳腺癌细胞的选择性给药，为攻克乳腺癌提供了新的前景。大约20%的乳腺癌为人类表皮生

快速一览： 近期乳腺癌研究新近进展

乳腺癌已成为当前社会的重大公共卫生问题。自20世纪90年代全球乳腺癌死亡率呈现出下降趋势；究其原因，一是乳腺癌筛查工作的开展，使早期病例的比例增加；二是乳腺癌综合治疗的开展，提高了疗效。乳腺癌已成为疗效最佳的实体肿瘤之一。梅斯小编汇总了近期乳腺癌相关的研究，与大家一起学习。【1】Science：雌激素受体（ER）阳性乳腺癌抵抗PI3K抑制剂疗法的原因PIK3CA基因的活化性突变在雌激素受体（E

SCI REP：分子亚型对转移性乳腺癌患者的影响

在世界范围内，乳腺癌是女性最常见的恶性肿瘤。大约有5-8%的患者在诊断时便出现远处转移，针对转移性乳腺癌患者治疗的主要目的是延长患者生存期以及改善症状。许多因素会影响转移性乳腺癌治疗的疗效，分子亚型便是其中重要的一种影响因素。

乳腺癌学习笔记（截止至17年3月）

最新的乳腺癌学习笔记，你值得拥有。

CA Cancer J Clin：第八版AJCC乳腺癌分期手册的主要变更内容

没时间看完整第八版AJCC乳腺癌分期手册，那就看看有哪些主要变更吧！

Cell Death & Disease：上海生科院发现肺转移性乳腺癌干细胞 并揭示其在乳腺癌转移中的作用机制

3月16日，国际学术期刊《细胞死亡和疾病》（Cell Death & Disease）在线发表了中国科学院上海生命科学研究院（人口健康领域）胡国宏研究组的最新研究成果“A CD44v+ subpopulation of breast cancer stem-like cells with enhanced lung metastasis capacity”，鉴定出了一个具有肺转移能力的乳腺癌干细胞

Baidu
map
Baidu
map
Baidu
map